Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06074120
Other study ID # 202307193DIND
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 12, 2024
Est. completion date December 31, 2024

Study information

Verified date September 2023
Source National Taiwan University Hospital
Contact Pei-chi Wu, MD.
Phone 0972651989
Email peggywu0707@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will employ a prospective single-arm design involving menopausal women who present with genitourinary symptoms of menopause (GSM). Due to the preliminary nature of this study and the absence of a control group, the primary objective is to evaluate the feasibility and potential efficacy of low-level laser therapy in alleviating GSM in this population.


Description:

A convenience sample of menopausal women aged more or equal to 45 years will be recruited from the gynecology clinic in our hospital and its branches. Participants will undergo an initial screening to confirm the presence of genitourinary symptoms associated with menopause. Inclusion criteria will encompass women experiencing symptoms such as urinary incontinence, vaginal dryness, dyspareunia, and decreased sexual satisfaction. The exclusion criteria will be diagnosed with advanced pelvic organ prolapse (more or equal to stage 2 prolapse by pelvic organ prolapse quantification system). All participants will receive low-level laser therapy (LLLT) as the intervention. LLLT sessions will be conducted once a week for eight weeks. The laser therapy will be administered by a trained healthcare professional using a standard protocol, targeting the genitourinary area. The laser device will emit low-energy laser light, which is hypothesized to stimulate tissue regeneration, improve blood circulation, and alleviate symptoms in the genitourinary region. Baseline assessments will be conducted prior to the initiation of LLLT, including demographic data collection and validated outcome measures to evaluate GSM and quality of life. These measures may include the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF), Female Sexual Function Index (FSFI), Vaginal Health Index (VHI), Incontinence Impact Questionnaire-7 (IIQ-7), Overactive Bladder Symptom Score (OABSS), Urogenital Distress Inventory-6 (UDI-6), Urgency Severity Scale (USS), King's Health Questionnaire (KHQ), and a urodynamic study with a 20-minute pad test. Follow-up assessments will be conducted immediately after the fourth- and eighth-week treatment period and at a three-month post-treatment follow-up. During these assessments, participants will complete the same validated outcome measures as the baseline assessment to evaluate changes in genitourinary symptoms and quality of life following LLLT.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 45 Years to 85 Years
Eligibility Inclusion Criteria: - Menopause women - With genitourinary symptoms of menopause Exclusion Criteria: - Acute or chronic infection of the genitourinary tract - Advanced pelvic organ prolapse (>= stage 2 on pelvic organ prolapse quantification system) - History of pelvic malignancy - Unstable blood pressure - Fever - Abnormal sensory nerve - Abnormal coagulation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Low-level laser therapy
Low-level laser therapy would be introduced via a vaginal probe (gain medium: Gallium-Aluminum-Arsenide, wavelength 660nm) for 30 minutes per treatment, once a week, for 8 courses.

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei City

Sponsors (2)

Lead Sponsor Collaborator
National Taiwan University Hospital National Taiwan University Hospital Beihu Branch

Country where clinical trial is conducted

Taiwan, 

References & Publications (6)

Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P, Shull BL, Smith AR. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996 Jul;175(1):10-7. doi: 10.1016/s0002-9378(96)7 — View Citation

Filippini M, Porcari I, Ruffolo AF, Casiraghi A, Farinelli M, Uccella S, Franchi M, Candiani M, Salvatore S. CO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis. J Sex Med. 2022 Mar;19(3):452-470. doi: 10.1016/ — View Citation

Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturitas. 2017 May;99:10-15. doi: 10.1016/j.maturitas.2017.01.012. Epub 2017 Feb 4. — View Citation

Long CY, Wu PC, Chen HS, Lin KL, Loo Z, Liu Y, Wu CH. Changes in sexual function and vaginal topography using transperineal ultrasound after vaginal laser treatment for women with stress urinary incontinence. Sci Rep. 2022 Mar 2;12(1):3435. doi: 10.1038/s — View Citation

Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause. 2021 Feb 1;28(5):579-588. doi: 10.1097/GME.0000000000001728. — View Citation

Rola P, Doroszko A, Derkacz A. The Use of Low-Level Energy Laser Radiation in Basic and Clinical Research. Adv Clin Exp Med. 2014 September-October;23(5):835-842. doi: 10.17219/acem/37263. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Vaginal health Vaginal health index, each of these 5 items is evaluated by means of a scale from 1 (none) to 5 (excellent) and then the average of the scores is calculated. A value of =15 (= cut-off) is generally considered for the diagnosis of low vaginal health. 20 weeks
Secondary Lower urinary tract symptom: incontinence ICIQ-SF: International Consultation on Incontinence Questionnaire - Short Form. Scoring scale: 0-21. Higher scores mean a worse outcome. 20 weeks
Secondary Lower urinary tract symptom: general UDI-6: Urogenital Distress Inventory-6. Scoring scale: 0-18. Higher scores mean a worse outcome. 20 weeks
Secondary Lower urinary tract symptom: life quality IIQ-7: Incontinence Impact Questionnaire-7. Scoring scale: 0-21. Higher scores mean a worse outcome. 20 weeks
Secondary Lower urinary tract symptom: urgency USS: Urgency Severity Scale. The USS is scored as 0 (no feeling of urgency), 1 (mild urgency), 2 (moderate urgency), 3 (severe urgency), or 4 (inability to hold urine). 20 weeks
Secondary Lower urinary tract symptom: overactive bladder OABSS: Overactive Bladder Symptom Score. The total score ranges from 0 to 15 points, with higher scores indicating higher symptom severity. 20 weeks
Secondary Quality of life affected by lower urinary tract symptoms KHQ: King's Health Questionnaire. It addresses nine different domains in 21 items with a Likert scale response options (range 1-4 and 1-5 on the first option). The domains are general health perception, incontinence impact, role limitations, physical and social limitations, personal relationships, emotions, sleep/energy, and severity coping measures. An additional independent scale with nine questions was designed to evaluate symptom severity perception. Scores for each domain are calculated through a complex system that manages missing values and results range from 0 to 100, with higher scores indicating a more impaired QoL. 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT05617287 - An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause N/A
Withdrawn NCT04258410 - Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency Phase 4
Recruiting NCT05912309 - Effects of Time-restricted Eating and Exercise Training on Skeletal Muscle Mass Quantity, Quality and Function in Postmenopausal Women With Overweight and Obesity N/A
Completed NCT04079218 - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial Phase 4
Active, not recruiting NCT03681678 - Laser Therapy for Treatment of Urogenital Symptoms in Women
Completed NCT03082040 - A Home-based Breathing Training on Menopausal Symptoms N/A
Recruiting NCT06048965 - Asia Pacific Menopause Federation Menopause Consensus
Terminated NCT03037554 - The Effects of Lateralized Thermal Sleepwear on Sleep, Skin Temperature and Skin Moisture in Menopausal Women N/A
Completed NCT03150407 - Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness N/A
Completed NCT04336891 - Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
Not yet recruiting NCT04190927 - A New Hormone Replacement Paradigm: Physiologic Restoration Study Phase 4
Completed NCT03178695 - Inovium Ovarian Rejuvenation Trials Phase 1
Completed NCT05408273 - Vitamin D and Microvascular Function in Postmenopausal Women
Recruiting NCT04031456 - Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients Phase 2/Phase 3
Completed NCT05062057 - Menopause Racing Heart Study
Completed NCT05396261 - a Flexible Wound Dressing for the Management of Genital Skin Conditions N/A
Completed NCT06154798 - World Digital Detox Program for Enhancing Women's Health & Well-being N/A
Completed NCT03752060 - The Clinical Utility of Resistance Training for Improving Cardiovascular Disease Risk in Post-Menopausal Women N/A
Recruiting NCT06192329 - Hot Water Therapy for the Treatment of Menopause-related Hot Flashes N/A
Not yet recruiting NCT06176820 - Vaginal Hyaluronic Acid, Arginine and Liposome Gel Versus Vaginal Lubricant in Postmenopausal Women With Genitourinary Syndrome of Menopause Phase 2/Phase 3